These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. NKG2A-Expressing Natural Killer Cells Dominate the Response to Autologous Lymphoblastoid Cells Infected with Epstein-Barr Virus. Hatton O; Strauss-Albee DM; Zhao NQ; Haggadone MD; Pelpola JS; Krams SM; Martinez OM; Blish CA Front Immunol; 2016; 7():607. PubMed ID: 28018364 [TBL] [Abstract][Full Text] [Related]
7. The Role of Lytic Infection for Lymphomagenesis of Human γ-Herpesviruses. Münz C Front Cell Infect Microbiol; 2021; 11():605258. PubMed ID: 33842383 [TBL] [Abstract][Full Text] [Related]
8. Induction of the Lytic Cycle Sensitizes Epstein-Barr Virus-Infected B Cells to NK Cell Killing That Is Counteracted by Virus-Mediated NK Cell Evasion Mechanisms in the Late Lytic Cycle. Williams LR; Quinn LL; Rowe M; Zuo J J Virol; 2016 Jan; 90(2):947-58. PubMed ID: 26537677 [TBL] [Abstract][Full Text] [Related]
9. Tonsillar CD56brightNKG2A+ NK cells restrict primary Epstein-Barr virus infection in B cells via IFN-γ. Jud A; Kotur M; Berger C; Gysin C; Nadal D; Lünemann A Oncotarget; 2017 Jan; 8(4):6130-6141. PubMed ID: 28008151 [TBL] [Abstract][Full Text] [Related]
10. Epidemiology of Epstein-Barr virus, cytomegalovirus, and Kaposi's sarcoma-associated herpesvirus infections in peripheral blood leukocytes revealed by a multiplex PCR assay. Nishiwaki M; Fujimuro M; Teishikata Y; Inoue H; Sasajima H; Nakaso K; Nakashima K; Sadanari H; Yamamoto T; Fujiwara Y; Ogawa N; Yokosawa H J Med Virol; 2006 Dec; 78(12):1635-42. PubMed ID: 17063511 [TBL] [Abstract][Full Text] [Related]
11. Latent cytomegalovirus infection enhances anti-tumour cytotoxicity through accumulation of NKG2C+ NK cells in healthy humans. Bigley AB; Rezvani K; Shah N; Sekine T; Balneger N; Pistillo M; Agha N; Kunz H; O'Connor DP; Bollard CM; Simpson RJ Clin Exp Immunol; 2016 Aug; 185(2):239-51. PubMed ID: 26940026 [TBL] [Abstract][Full Text] [Related]
12. NK Cell Influence on the Outcome of Primary Epstein-Barr Virus Infection. Chijioke O; Landtwing V; Münz C Front Immunol; 2016; 7():323. PubMed ID: 27621731 [TBL] [Abstract][Full Text] [Related]
16. CD56-negative NK cells with impaired effector function expand in CMV and EBV co-infected healthy donors with age. Müller-Durovic B; Grählert J; Devine OP; Akbar AN; Hess C Aging (Albany NY); 2019 Jan; 11(2):724-740. PubMed ID: 30686790 [TBL] [Abstract][Full Text] [Related]
17. STAT3 Regulates Lytic Activation of Kaposi's Sarcoma-Associated Herpesvirus. King CA; Li X; Barbachano-Guerrero A; Bhaduri-McIntosh S J Virol; 2015 Nov; 89(22):11347-55. PubMed ID: 26339061 [TBL] [Abstract][Full Text] [Related]
18. Selective switch between latency and lytic replication of Kaposi's sarcoma herpesvirus and Epstein-Barr virus in dually infected body cavity lymphoma cells. Miller G; Heston L; Grogan E; Gradoville L; Rigsby M; Sun R; Shedd D; Kushnaryov VM; Grossberg S; Chang Y J Virol; 1997 Jan; 71(1):314-24. PubMed ID: 8985352 [TBL] [Abstract][Full Text] [Related]
19. Peripheral blood lymphocytes resistant to Epstein-Barr virus immortalization manifest high natural killer (NK) type activity against NK-resistant target cells. Gosselin J; Menezes J; Mercier G; Lamoureux G; Oth D Viral Immunol; 1990; 3(1):55-65. PubMed ID: 2153385 [TBL] [Abstract][Full Text] [Related]
20. Manipulation of the host cell membrane by human γ-herpesviruses EBV and KSHV for pathogenesis. Wei F; Zhu Q; Ding L; Liang Q; Cai Q Virol Sin; 2016 Oct; 31(5):395-405. PubMed ID: 27624182 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]